It started in the early 1990s as a registry of patients with a heart condition. Today, data from more than 2,000 families with dilated cardiomyopathy is informing the next generation of therapies for this serious disease.
Together, cardiologist Luisa Mestroni, MD, and geneticist Matthew Taylor, MD, PhD, both professors in the Division of Cardiology at the University of Colorado School of Medicine, have helped thousands of patients in the clinic. They’ve also studied many of the over 50 genes associated with dilated cardiomyopathy (DCM). In the following Q&A, they explain their research and the gene therapy clinical trials that will be launching on the CU Anschutz Medical Campus during the first half of 2024.